Research

Mixed

GLP-1 receptor agonists (GLP-1RAs) may reduce the severity of Obstructive Sleep Apnoea (OSA) as measured by the Apnoea-Hypopnoea Index (AHI), primarily through weight loss mechanisms, though evidence quality is currently low and results are conflicting.

If you have OSA and are considering GLP-1RAs (like semaglutide or liraglutide), expect a modest improvement in sleep breathing (AHI) rather than a cure. The benefit is largely tied to weight loss. Do not stop using your CPAP machine unless your doctor advises it, as CPAP is currently more effective. Be prepared for potential stomach side effects, which are common but often subside. The evidence is not yet strong enough to make this a standard first-line treatment for OSA alone.

LimitedConditionalLOW confidence
This scoping review identified early evidence to suggest that GLP-1RAs may improve OSA as defined by reduction in apnoea-hypopnoea index (AHI). This evidence is however conflicting due to contradicting results demonstrated from other studies.
Khang Duy Ricky Le et al. · Pharmacy · 2024

Why this rating

The review explicitly states the evidence is 'low quality' with 'short lengths of follow-up' and 'conflicting results'.

Source

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review

Khang Duy Ricky Le et al. · Pharmacy · 2024

DOI 10.3390/pharmacy12010011

narrative_reviewCited 36×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →